Ceftaroline Fosamil for the Treatment of Gram-Positive Endocarditis: CAPTURE Study Experience.
Int J Antimicrob Agents. 2019 Jan 31;:
Authors: Destache CJ, Guervil DJ, Kaye KS
BACKGROUND: The clinical experience of ceftaroline fosamil (CPT-F) therapy for gram-positive infective endocarditis is reported from CAPTURE, a retrospective study conducted in the United States.
METHODS: Data, including patient demographics, medical history, risk factors, microbiological etiology, and clinical outcomes, were collected by review of patient charts between September 2013 and February 2015.
RESULTS: Patients (n=55) with gram-positive endocarditis were treated with CPT-F. Most common risk factors were intravascular devices (43.6%), diabetes mellitus (40.0%), and injection drug use (38.2%). Most commonly isolated pathogens were methicillin-resistant Staphylococcus aureus (MRSA; 80%), methicillin-susceptible S aureus (MSSA; 7.3%), and coagulase-negative Staphylococci (7.3%). CPT-F was given as a first-line treatment in 7.3% of patients, as ≥ second-line treatment in 92.7% of patients, and as monotherapy in 41.8% of patients and concurrent therapy in 58.2% of patients. Clinical success was observed in 82.6% (19/23) of patients treated with CPT-F as monotherapy. In patients treated with CPT-F as a first- or ≥ second-line therapy, 75.0% (3/4) and 70.6% (36/51) achieved success, respectively. Clinical success was observed in 77.3% (34/44) patients with MRSA and 25% (1/4) of patients with MSSA. Two patients discontinued treatment with CPT-F owing to an adverse event.
CONCLUSIONS: CPT-F treatment was associated with a high rate of clinical success in patients with gram-positive infective endocarditis, including those with risk factors, and infections caused by MRSA. A high rate of clinical success was observed in patients treated with CPT-F used as first- or ≥ second-line therapy or as monotherapy or in combination with other antibiotics.
PMID: 30711613 [PubMed - as supplied by publisher]